Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors
暂无分享,去创建一个
[1] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Wei Zhou,et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.
[3] Hong Zhou,et al. Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis , 2004, Cancer Research.
[4] Charles M. Perou,et al. Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.
[5] John M S Bartlett,et al. Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients , 2009, Clinical Cancer Research.
[6] J. Jardillier,et al. Multicellular resistance: a paradigm for clinical resistance? , 2000, Critical reviews in oncology/hematology.
[7] Sophie Lelièvre,et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.
[8] F. Hobbs,et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.
[9] C. Graham,et al. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells , 2006, Breast Cancer Research and Treatment.
[10] R. Kerbel,et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.
[11] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[12] Mina J Bissell,et al. Modeling tissue-specific signaling and organ function in three dimensions , 2003, Journal of Cell Science.
[13] M. Tainsky,et al. The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines , 2006, Journal of Pharmacology and Experimental Therapeutics.
[14] R. Mattingly,et al. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. , 2008, Neoplasia.
[15] Laura M. Heiser,et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.
[16] C. Ries,et al. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab , 2009, Oncogene.
[17] R. Hansen,et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. , 2002, Journal of the National Cancer Institute.
[18] Juergen Friedrich,et al. Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge? , 2007, International journal of radiation biology.
[19] Bonnie F. Sloane,et al. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. , 2008, Neoplasia.
[20] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[21] M. Ihnat,et al. A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. , 2005, Cancer letters.
[22] W. Franklin,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Nissi M. Varki,et al. Ras activation in human breast cancer , 2000, Breast Cancer Research and Treatment.
[24] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[25] C. Larabell,et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. Kerbel,et al. Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.
[27] B. Mirkin,et al. Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. , 2001, Cellular signalling.
[28] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[29] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[30] J. Sebolt-Leopold,et al. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). , 2003, Seminars in oncology.